News Archive

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2016 Archives

Dec 16, 2016
Dec 8, 2016
Dec 6, 2016
--Patent offers protection through February 2030--
Dec 1, 2016
--Company seeks to strengthen label with abuse-deterrent data that shows OXAYDO resists syringeability--
Nov 17, 2016
Nov 4, 2016
--Webcast and conference call at 8:30 AM EDT--
Oct 28, 2016
Oct 20, 2016
Oct 13, 2016
No additional scientific information or data requested by FDA
Sep 27, 2016
Sep 22, 2016
Sep 19, 2016
Sep 15, 2016
Sep 12, 2016
Sep 8, 2016
--Data presented today at PAINWeek 2016--
Aug 31, 2016
--An additional $40 million to be funded if ARYMO™ ER is approved by June 2017--
Aug 25, 2016
--Six posters to be presented including several highlighting abuse-deterrent profile of ARYMO™ ER and one on syringeability of OXAYDO®--
Aug 4, 2016
--Committees voted that if approved ARYMO ER should be labeled as an abuse-deterrent product by the intravenous, nasal and oral routes of abuse--
Jul 21, 2016
Jul 19, 2016
--Patents cover extended-release formulations of opioids, and immediate-release formulations intended to resist 'dose dumping' for opioids--
Jul 7, 2016
Jun 28, 2016
Jun 13, 2016
Jun 10, 2016
May 23, 2016
--No financial obligations to either party--
 

 

 

CAREERS

Find out more about opportunities with Zyla Life Sciences.

Career Contact
careers@zyla.com

QUICK LINKS

Sign up for Zyla Life Sciences email alerts.

Investor Contact
ir@zyla.com
Media Contact
media@zyla.com

ZYLA LIFE SCIENCES

U.S. Operations
600 Lee Road, Suite 100
Wayne, PA 19087
Tel: 610.833.4200

© Copyright 2019 Zyla Life Sciences
All rights reserved.